Phase 3 N=157 The Study Of Fluconazole For Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Therapeutic Outcome: Response Rate — 33.7; 54.2; 74.7 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=26 Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate at Day 7-14 — 10; 16 Participants
Phase 2 N=55 A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
Candidiasis, Vulvovaginal
Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants
Phase 4 N=85 Negative Beta Glucan in ICU Patients
Candidemia
Primary: Evaluate the Ocurrence of Candidemia in Patients With Negative 1,3 Beta-D-glucan Who Discontinue Anidulafungin — 0; 21 Participants
N/A N=47 Radiofrequency and Hybrid Fractional Laser for Vaginal Rejuvenation
Vaginal Atrophy
Primary: Vulvovaginal Symptoms Questionnaire — 8; 7.88; 5.93; 5.93 score on a scale
Phase 3 N=219 Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections
Recurrent Vulvovaginal Candidiasis
Primary: Percentage of Subjects With 1 or More Culture-verified Acute VVC Episodes During the Maintenance Phase of the Study in the Intent-to-treat (ITT) Population — 5.1; 42.2…
Phase 4 N=140 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Mycological Cure 1 — 46; 47 Participants
N/A N=572 Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Proportion of Subjects in Each Treatment Group With Therapeutic Cure — 105; 93 participants
Phase 2 N=188 Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Summary of Injection Site Reactions for the Safety Population Over the 12-months Post Vaccination Period — 72; 79; 10; 25 AEs
Phase 2 N=186 Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
Candida Vulvovaginitis
Primary: Clinical Cure (Complete Resolution of Signs and Symptoms) — 9; 14; 13; 14 Participants
Phase 2 N=229 Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Vulvovaginal Candidiasis
Primary: Dose-response of Clinical and Mycological (Global) Therapeutic Response — 31.7; 48.7; 47.6; 53.8 percentage of patients cured — p=0.0630
Phase 4 N=240 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Candidiasis, Vulvovaginal
Primary: Therapeutic Efficacy 1 — 102; 98 participants — p=0.925
Phase 3 N=63 A Study of Caspofungin Acetate (MK0991) for the Treatment of Esophageal Candidiasis or Invasive Candidiasis in Chinese Adults (MK-0991-066)
Fungal Infection
Primary: Number of Participants With One or More Drug-related Serious Adverse Events — 0 Participants
Phase 2 N=283 Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy
Vaginal Atrophy
Primary: Change From Baseline to Week 12 in the Severity of Vaginal Dryness — 15; 13; 13; 9 Participants — p==0.304
N/A N=23 Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Clinical Cure Rate — 9 Participants